leadf
logo-loader
viewAntibe Therapeutics Inc

Antibe Therapeutics adds biotech executive Don Haut to its Partnering Advisory Team

Antibe CEO Dan Legault said Haut's background and recent success will "add new depth" to the firm's business development capabilities

Antibe Therapeutics Inc -
Haut recently served as the chief business officer of AskBio, a clinical stage developer of gene therapies and technologies

Antibe Therapeutics Inc (TSE:ATE) (OTCQB:ATBPF) (FRA:4B70) is bolstering its advisory team with the appointment of biotech executive Dr Don Haut to its Partnering Advisory Team. 

Haut recently served as the chief business officer of AskBio, a clinical-stage developer of gene therapies and technologies. During his tenure at the company, Haut played a key role in pharmaceutical giant Bayer AG’s $4 billion acquisition of AskBio. 

Haut earned his PhD in molecular biology from the Medical School at the University of Missouri-Columbia and an MBA from Washington University’s Olin School of Business.

READ: Antibe Therapeutics plans to unify the intellectual property ownership of its drugs and platform

“I am delighted to welcome another superstar to our Partnering Advisory Team,” said Dan Legault, Antibe’s CEO in a statement. “Don’s broad background and tremendous recent success will add new depth to our business development capability as our partnering activities accelerate in 2021.”

Haut told shareholders that Antibe’s platform “promises a major advance” in the treatment of pain and inflammation-based disease.

“This area is overdue for disruption and represents a massive commercial opportunity,” Haut said. “I’m excited to put my shoulder to the wheel to help Antibe fully capture the value of its pipeline as it enters late-stage development.”

Toronto-based Antibe is developing a platform of unique drugs designed to prevent serious gastrointestinal damage and bleeding caused using non-steroidal anti-inflammatory drugs known as NSAIDs, which are currently the primary therapy for pain relief.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Quick facts: Antibe Therapeutics Inc

Price: 4.68 CAD

TSX:ATE
Market: TSX
Market Cap: $212.97 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Antibe Therapeutics Inc named herein, including the promotion by the Company of Antibe Therapeutics Inc in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Antibe Therapeutics releases data from company’s Phase II placebo-controlled...

Antibe Therapeutics (CVE: ATE) CEO Dan Legault joined Steve Darling from Proactive Vancouver with new results from the company’s analysis of primary and secondary data from ATB-346’s recent placebo-controlled efficacy trial. Legault shares the data with Proactive and he also maps out the...

on 08/12/2020

2 min read